At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Radium Ra 223 Dichloride +1 moredrug
Likely dose
Enzalutamide 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Radium Ra 223 Dichloride and Enzalutamide for Prostate Cancer. Completed, enrolled 49 participants across 1 site.
Detailed Summary
Study of Radium Ra 223 dichloride with enzalutamide compared to enzalutamide alone in men with metastatic castration refractory prostate cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJul 2014
Primary CompletionApr 2018
Study CompletionOct 2019
TodayJul 2026
First PostedJul 24, 2014
Enrollment StartJun 25, 2014
Primary CompletionApr 19, 2018
Study CompletionOct 3, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.9 years ago
Interventions
Radium Ra 223 Dichloridedrug
Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
Enzalutamidedrug
Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.